CSPC Group (01093.HK) spent HK$34.5693 million to buy back 6 million shares on April 19
Gelonghui, April 19 | Shiyao Group (01093.HK) announced that on April 19, it spent HK$34.5693 million to repurchase 6 million shares, with a repurchase price of HK$5.66-5.82 per share.
白雲山:2023年年報
China Biopharmaceutical (01177.HK) obtained Xie Qirun to increase its common shares by 2.5 million shares, worth approximately HK$5.8057 million
On April 19, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 19, Xie Qirun increased its common stock holdings of $2.5 million in China Biopharmaceuticals (01177.HK) at an average price of HK$2.3223 per share on April 19, worth about HK$5.8057 million. After the increase in holdings, Xie Qirun's latest shareholding was 4 million shares, and the good position ratio increased from 0.01% to 0.02%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Listed public
A quick look at the Hong Kong market | Tech Index fell more than 2%, Tech Net stocks generally declined, and Xiaomi and Kuaishou fell more than 3%
Auto stocks declined, with Ideal Auto and Xiaopeng Motors falling more than 7%; petroleum stocks reversed the market and CNPC rose more than 2%.
Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug
Sino Biopharmaceutical's (HKG:1177) key clinical research for the registration of Rovadicitinib has met its primary endpoint, a Thursday filing on the Hong Kong bourse stated. The pharmaceutical compa
Damo: Target price for Sinopharm Holdings (01099) “increase in holdings” rating reduced to HK$28
Sinopharm Holdings (01099) has stable profit margins, and changes in business structure and efficiency improvements offset price reductions.